Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II trial of INO 4800 in China

Trial Profile

Phase I/II trial of INO 4800 in China

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2020

At a glance

  • Drugs INO 4800 (Primary)
  • Indications COVID 2019 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Aug 2020 According to an Inovio Pharmaceuticals media release, regulatory authorities in China approved the clinical testing of INO-4800 by Advaccine in China, in July.
    • 03 Mar 2020 According to Inovio Pharmaceuticals, Inc. media release, the company plans to publish/present results in Fall 2020.
    • 03 Mar 2020 According to Inovio Pharmaceuticals, Inc. media release,the company plans to initiate this trial in April 2020.

Trial Overview

Purpose

This phase 1 trial will evaluate INO 4800 in China.

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections prevention -

Subjects

  • Subject Type patients
  • Sex male & female

Trial Details

Organisations

  • Affiliations Beijing Advaccine Biotechnology; Inovio Pharmaceuticals

Trial Dates

Other Details

  • Design prospective
  • Phase of Trial Phase I/II
  • Location China
  • Focus Adverse reactions

Interventions

Drugs Route Formulation
INO 4800Primary Drug Parenteral
-

INO 4800

Trial History

Event Date Event Type Comment
10 Aug 2020 Other trial event According to an Inovio Pharmaceuticals media release, regulatory authorities in China approved the clinical testing of INO-4800 by Advaccine in China, in July. Updated 13 Aug 2020
03 Mar 2020 Other trial event According to Inovio Pharmaceuticals, Inc. media release, the company plans to publish/present results in Fall 2020. Updated 09 Mar 2020
03 Mar 2020 Other trial event According to Inovio Pharmaceuticals, Inc. media release,the company plans to initiate this trial in April 2020. Updated 09 Mar 2020
04 Feb 2020 New trial record New trial record Updated 04 Feb 2020
30 Jan 2020 Other trial event According to an Inovio Pharmaceuticals media release, it is collaborating with Beijing Advaccine Biotechnology Co. to advance the development of INO-4800 in China. Updated 05 Feb 2020

References

  1. Inovio Pharmaceuticals. Inovio Collaborating With Beijing Advaccine To Advance INO-4800 Vaccine Against New Coronavirus In China. Media-Rel 2020;.

    Media Release
  2. Inovio Pharmaceuticals. Inovio Accelerates Timeline for COVID-19 DNA Vaccine INO-4800. Media-Rel 2020;.

    Media Release
  3. Inovio Pharmaceuticals. INOVIO's COVID-19 DNA Vaccine INO-4800 Provides Protection with Memory Immune Responses In Non-Human Primates Challenged with SARS-CoV-2 Virus. Media-Rel 2020;.

    Media Release
  4. Inovio Pharmaceuticals. INOVIO Reports Second Quarter 2020 Financial Results; Provides DNA Medicines Clinical Program Mid-Year Update. Media-Rel 2020;.

    Media Release
Back to top